Treatment of Diabetes in Patients with Established ASCVD or CKD

Adapted from Cardiac benefits in Diabetes Therapy: Comparing SGLT2 Inhibitors and GLP-1 Agonists
By Samuel Grossman, BS Pharm, PharmD, CDE, FAADE

Either/or

ASCVD
- GLP-1 RA
- SGLT2 (if eGFR adequate)

HF or CKD
- SGLT2 (if eGFR adequate)
- GLP-1 RA

If eGFR not adequate or SGLT2 not tolerated

References:
- Diabetes Care 2019;42 (suppl. 1):s39